Skip to content

Retinoblastoma — overview

TL;DR — Retinoblastoma is a malignant tumour of the developing retina, usually diagnosed in infancy, caused most often by biallelic RB1 inactivation in a susceptible retinal cell. Knudson's analysis of 48 cases supplied the two-hit model; modern molecular work points to cone-lineage susceptibility rather than indiscriminate vulnerability of all retinal cells. Three-year survival was 99.5% in high-income settings but 57.3% in low-income countries in the 2017 global cohort, principally tracking extraocular presentation; survival at three years is not the same as cure, and heritable survivors carry decades of further risk. Treatment must order life, globe, then useful vision; heritable disease also creates lifelong subsequent-neoplasm risk.

Decision-relevant evidence

  • Knudson inferred two mutational events from age and laterality patterns in 48 cases; a germline first event explains bilateral, multifocal and occasional nonpenetrant presentations, and he calculated a mean of about three tumours per carrier (Knudson 1971, PMID 5279523).

  • The disease primer estimates approximately 8,000 diagnoses annually, identifies the susceptible cell as probably a cone photoreceptor precursor, and contrasts survival above 95% in high-income countries with below 30% globally (Dimaras 2015, PMID 27189421).

  • In 4,064 treatment-naive children from 149 countries, median age at diagnosis was 23.2 months (IQR 11.0–36.5) (Global Retinoblastoma Study Group 2022, PMID 35839812).

  • Three-year survival ranged from 99.5% (95% CI 98.8–100.0) in high-income countries to 91.2% (89.5–93.0), 80.3% (78.3–82.3) and 57.3% (52.1–63.0) across upper-middle-, lower-middle- and low-income countries, while cT4 presentation ran 0.8%, 5.4%, 19.7% and 42.9% across the same strata (PMID 35839812).

  • Availability of treatment did not close that gap: enucleation was available for every enrolled child and intravenous chemotherapy for 98.8%, so the gradient is a timing and completion problem rather than a drug-supply problem (PMID 35839812).

  • Heritable survivors had an overall subsequent-malignancy SIR of 11.9 (95% CI 10.4–13.5) and a 50-year cumulative incidence of 33.1% (29.0–37.2) for a first subsequent neoplasm; non-heritable survivors had SIR 0.8 (0.5–1.2) (Schonfeld 2021, PMID 33473166).

  • The 3.1–17 interval in Schonfeld is a range across melanoma, CNS, oral-cavity and breast cancers, not a melanoma-specific point estimate (PMID 33473166).

  • Randomized evidence now exists for two treatment decisions that were previously settled by preference: intra-arterial versus intravenous chemotherapy for advanced unilateral disease (two-year progression-free globe salvage 53% versus 27%, RR 1.97, 95% CI 1.27–3.07, in 143 children) and three versus six adjuvant cycles after high-risk enucleation (five-year disease-free survival 90.4% versus 89.2%, difference 1.2%, 95% CI −7.5 to 9.8, in 187 patients) (Wen 2023, PMID 37536351; Ye 2024, PMID 39432296).

  • Eye-level and child-level results diverge sharply by stage: with systemic chemotherapy plus focal therapy, salvage was 95% for cT1, 56% for cT2 and 0% for cT3 eyes in a 565-eye series (Yousef 2021, PMID 33769386), while for extraocular disease treated on ARET0321 one-year event-free survival was 88.1% for stage II–III but 28.3% for stage IVb/trilateral (Dunkel 2022, PMID 35820112).

  • Delay is measurable and decomposable rather than a general lament: in 1,120 Indian children the mean symptom-to-treatment interval was 4.2 months, split 44% parental, 26% diagnostic and 31% treatment-initiation, and 25.2% already had extraocular or metastatic disease (Das 2025, PMID 40719713).

Clinical and research frame

Domain Operational meaning Evidence boundary
Immediate objective Prevent metastatic death Stage and access dominate
Second objective Preserve an eye when oncologically safe Globe salvage is not equivalent to sight
Third objective Preserve useful vision Macular/optic-nerve anatomy and toxicity matter
Lifetime objective Identify heritable disease and late effects Genetics changes relatives' care and survivor risk

Interpretation rules

  • Keep the child-level endpoints of survival and metastasis separate from the eye-level endpoint of globe salvage.

  • Report initial stage, laterality, heritability, prior treatment and follow-up; otherwise comparisons are not transportable.

  • A retrospective eye series estimates performance in selected eyes; it does not establish superiority over another route.

  • Absence of metastasis in a small series is a safety observation, not proof that risk is zero.

  • Treatment-era effects matter because external-beam radiotherapy, systemic chemotherapy, IAC and intravitreal therapy create different late-risk profiles.

  • Income stratum and access are effect modifiers, not background descriptors (Global Retinoblastoma Study Group 2022, PMID 35839812).

Evidence register

The following records were each retrieved live from PubMed E-utilities on 2026-09-01 and re-fetched live during the independent audit on the same date. Every identifier below resolved, and its author, year, journal and title matched the citation as written. Inclusion records the evidence base for this page; a register entry asserts that the record exists and is on topic, not that it supports a specific effect estimate.

PMID Year Study or review Role in this page
5279523 1971 Mutation and cancer: statistical study of retinoblastoma. Topic-resolved source (Knudson 1971, PMID 5279523)
27189421 2015 Retinoblastoma. Topic-resolved source (Dimaras 2015, PMID 27189421)
35839812 2022 The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Topic-resolved source (Global 2022, PMID 35839812)
33473166 2021 Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors. Topic-resolved source (Schonfeld 2021, PMID 33473166)
38804799 2024 Retinoblastoma - A comprehensive review, update and recent advances. Topic-resolved source (Nag 2024, PMID 38804799)
28620731 2017 Retinoblastoma. Topic-resolved source (Rao 2017, PMID 28620731)
26023180 2016 Retinoblastoma. Topic-resolved source (Ortiz 2016, PMID 26023180)
22414599 2012 Retinoblastoma. Topic-resolved source (Dimaras 2012, PMID 22414599)
41002743 2025 A Comprehensive Review of the Epidemiology, Pathophysiology, Risk Factors, and Treatment Strategies for Retinoblastoma. Topic-resolved source (Kumari 2025, PMID 41002743)
38492167 2024 Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines. Topic-resolved source (Singh 2024, PMID 38492167)
33583507 2021 Neonatal Retinoblastoma. Topic-resolved source (Lin 2021, PMID 33583507)
27609158 2016 Adult onset retinoblastoma. Topic-resolved source (Sengupta 2016, PMID 27609158)
34226484 2021 Retinoblastoma: A Major Review. Topic-resolved source (Roy 2021, PMID 34226484)
34210807 2021 Update on the Treatment of Retinoblastoma. Topic-resolved source (Manrique 2021, PMID 34210807)
29737052 2018 Retinoblastoma for Pediatric Ophthalmologists. Topic-resolved source (AlAli 2018, PMID 29737052)
16382314 2006 [Retinoblastoma]. Topic-resolved source (Bornfeld 2006, PMID 16382314)
34648817 2022 Cavitary retinoblastoma: A review of literature. Topic-resolved source (Raval 2022, PMID 34648817)
15579980 2004 Update on retinoblastoma. Topic-resolved source (Abramson 2004, PMID 15579980)
26679524 2016 [Retinoblastoma update]. Topic-resolved source (Aerts 2016, PMID 26679524)
32105305 2020 Global Retinoblastoma Presentation and Analysis by National Income Level. Topic-resolved source (Global 2020, PMID 32105305)
29321667 2018 The management of retinoblastoma. Topic-resolved source (Fabian 2018, PMID 29321667)
22421935 2012 Retinoblastoma: an overview. Topic-resolved source (Ray 2012, PMID 22421935)
30908283 2019 Retinoblastoma: What is the future? Topic-resolved source (Singh 2019, PMID 30908283)
24793631 2014 [Retinoblastoma: recent advances]. Topic-resolved source (Jehanne 2014, PMID 24793631)
3819329 1986 [Retinoblastoma: 21-year review]. Topic-resolved source (Kayembe 1986, PMID 3819329)
33801943 2021 Subsequent Malignant Neoplasms in Retinoblastoma Survivors. Topic-resolved source (Fabius 2021, PMID 33801943)
37667345 2023 Retinoblastoma: present scenario and future challenges. Topic-resolved source (Byroju 2023, PMID 37667345)
33120616 2020 Modern treatment of retinoblastoma: A 2020 review. Topic-resolved source (Ancona-Lezama 2020, PMID 33120616)
38615905 2024 Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Topic-resolved source (Zhou 2024, PMID 38615905)
34987197 2023 Retinoblastoma and vision. Topic-resolved source (Warda 2023, PMID 34987197)
25435120 2015 Retinoblastoma. Topic-resolved source (Rodriguez-Galindo 2015, PMID 25435120)
16570739 2006 Retinoblastoma. Topic-resolved source (Melamud 2006, PMID 16570739)
24100372 2013 Retinoblastoma. Topic-resolved source (Villegas 2013, PMID 24100372)
16572402 2007 Trilateral retinoblastoma. Topic-resolved source (Antoneli 2007, PMID 16572402)
16934146 2006 Retinoblastoma. Topic-resolved source (Aerts 2006, PMID 16934146)
28558178 2017 Retinoblastoma: Update on Current Management. Topic-resolved source (Cassoux 2017, PMID 28558178)
8199450 1993 Retinoblastoma. Topic-resolved source (Abramson 1993, PMID 8199450)
22337189 2012 Retinoblastoma. Topic-resolved source (Mehta 2012, PMID 22337189)
2059954 1991 Retinoblastoma. Topic-resolved source (Servodidio 1991, PMID 2059954)
30385881 2019 Retinoblastoma in Asia. Topic-resolved source (Jain 2019, PMID 30385881)
37536351 2023 Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial. Added by audit 2026-09-01 (Wen 2023, PMID 37536351)
39432296 2024 Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma: A Randomized Clinical Trial. Added by audit 2026-09-01 (Ye 2024, PMID 39432296)
33769386 2021 The Predictive Value of the Eighth Edition of the Clinical TNM Staging System for the Likelihood of Eye Salvage for Intraocular Retinoblastoma by Systemic Chemotherapy and Focal Therapy. Added by audit 2026-09-01 (Yousef 2021, PMID 33769386)
35820112 2022 Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). Added by audit 2026-09-01 (Dunkel 2022, PMID 35820112)
40719713 2025 Lag time for diagnosis and treatment in 1120 retinoblastoma children: Analysis from InPOG-RB-19-01. Added by audit 2026-09-01 (Das 2025, PMID 40719713)

Source chronology

Era marker PMID What the record contributes
1971 5279523 Mutation and cancer: statistical study of retinoblastoma. (Knudson 1971, PMID 5279523)
1986 3819329 [Retinoblastoma: 21-year review]. (Kayembe 1986, PMID 3819329)
1991 2059954 Retinoblastoma. (Servodidio 1991, PMID 2059954)
1993 8199450 Retinoblastoma. (Abramson 1993, PMID 8199450)
2004 15579980 Update on retinoblastoma. (Abramson 2004, PMID 15579980)
2006 16382314 [Retinoblastoma]. (Bornfeld 2006, PMID 16382314)
2006 16570739 Retinoblastoma. (Melamud 2006, PMID 16570739)
2006 16934146 Retinoblastoma. (Aerts 2006, PMID 16934146)
2007 16572402 Trilateral retinoblastoma. (Antoneli 2007, PMID 16572402)
2012 22337189 Retinoblastoma. (Mehta 2012, PMID 22337189)
2012 22414599 Retinoblastoma. (Dimaras 2012, PMID 22414599)
2012 22421935 Retinoblastoma: an overview. (Ray 2012, PMID 22421935)
2013 24100372 Retinoblastoma. (Villegas 2013, PMID 24100372)
2014 24793631 [Retinoblastoma: recent advances]. (Jehanne 2014, PMID 24793631)
2015 25435120 Retinoblastoma. (Rodriguez-Galindo 2015, PMID 25435120)

Evidence limitations

  • Most intraocular treatment evidence is observational, single-centre and reported per eye; bilateral eyes within one child are statistically correlated.

  • Classification and treatment changed over time, producing stage migration and confounding by indication.

  • Rare metastatic and late-effect outcomes require multinational cohorts and decades of follow-up.

  • Verification is abstract-level. Every claim on this page was checked against the abstract of the record it cites during the independent audit on 2026-09-01; where an abstract could not support a claim, the claim was removed or restated as an explicit limit. Claims requiring full text beyond the abstract are not made here.

Open questions

  • Which components of diagnostic delay are independently modifiable across income strata? The current evidence register defines the design space but does not close the question.

  • Which modern eye-salvage strategies preserve useful vision rather than only the globe? The current evidence register defines the design space but does not close the question.

  • How should lifelong surveillance be tested in heritable survivors when routine imaging lacks evidence? The current evidence register defines the design space but does not close the question.

References

  1. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America. 1971;68:820-3. PMID 5279523
  2. Dimaras H, et al. Retinoblastoma. Nature reviews. Disease primers. 2015;1:15021. PMID 27189421
  3. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet. Global health. 2022;10:e1128-e1140. PMID 35839812
  4. Schonfeld SJ, et al. Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors. British journal of cancer. 2021;124:1312-1319. PMID 33473166
  5. Nag A, et al. Retinoblastoma - A comprehensive review, update and recent advances. Indian journal of ophthalmology. 2024;72:778-788. PMID 38804799
  6. Rao R, et al. Retinoblastoma. Indian journal of pediatrics. 2017;84:937-944. PMID 28620731
  7. Ortiz MV, et al. Retinoblastoma. Journal of child neurology. 2016;31:227-36. PMID 26023180
  8. Dimaras H, et al. Retinoblastoma. Lancet (London, England). 2012;379:1436-46. PMID 22414599
  9. Kumari A, et al. A Comprehensive Review of the Epidemiology, Pathophysiology, Risk Factors, and Treatment Strategies for Retinoblastoma. Diseases (Basel, Switzerland). 2025;13. PMID 41002743
  10. Singh L, et al. Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines. Indian journal of pediatrics. 2024;91:1147-1156. PMID 38492167
  11. Lin FY, et al. Neonatal Retinoblastoma. Clinics in perinatology. 2021;48:53-70. PMID 33583507
  12. Sengupta S, et al. Adult onset retinoblastoma. Indian journal of ophthalmology. 2016;64:485-91. PMID 27609158
  13. Roy SR, et al. Retinoblastoma: A Major Review. Mymensingh medical journal : MMJ. 2021;30:881-895. PMID 34226484
  14. Manrique M, et al. Update on the Treatment of Retinoblastoma. NeoReviews. 2021;22:e423-e437. PMID 34210807
  15. AlAli A, et al. Retinoblastoma for Pediatric Ophthalmologists. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2018;7:160-168. PMID 29737052
  16. Bornfeld N, et al. [Retinoblastoma]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2006;103:59-76; quiz 77-8. PMID 16382314
  17. Raval V, et al. Cavitary retinoblastoma: A review of literature. Survey of ophthalmology. 2022;67:723-728. PMID 34648817
  18. Abramson DH, et al. Update on retinoblastoma. Retina (Philadelphia, Pa.). 2004;24:828-48. PMID 15579980
  19. Aerts I, et al. [Retinoblastoma update]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. 2016;23:112-6. PMID 26679524
  20. Global Retinoblastoma Study Group, et al. Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA oncology. 2020;6:685-695. PMID 32105305
  21. Fabian ID, et al. The management of retinoblastoma. Oncogene. 2018;37:1551-1560. PMID 29321667
  22. Ray A, et al. Retinoblastoma: an overview. Indian journal of pediatrics. 2012;79:916-21. PMID 22421935
  23. Singh AD. Retinoblastoma: What is the future? International ophthalmology clinics. 2019;59:95-99. PMID 30908283
  24. Jehanne M, et al. [Retinoblastoma: recent advances]. Bulletin du cancer. 2014;101:380-7. PMID 24793631
  25. Kayembe L. [Retinoblastoma: 21-year review]. Journal francais d'ophtalmologie. 1986;9:561-5. PMID 3819329
  26. Fabius AWM, et al. Subsequent Malignant Neoplasms in Retinoblastoma Survivors. Cancers. 2021;13. PMID 33801943
  27. Byroju VV, et al. Retinoblastoma: present scenario and future challenges. Cell communication and signaling : CCS. 2023;21:226. PMID 37667345
  28. Ancona-Lezama D, et al. Modern treatment of retinoblastoma: A 2020 review. Indian journal of ophthalmology. 2020;68:2356-2365. PMID 33120616
  29. Zhou M, et al. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2024;13:100058. PMID 38615905
  30. Warda O, et al. Retinoblastoma and vision. Eye (London, England). 2023;37:797-808. PMID 34987197
  31. Rodriguez-Galindo C, et al. Retinoblastoma. Pediatric clinics of North America. 2015;62:201-23. PMID 25435120
  32. Melamud A, et al. Retinoblastoma. American family physician. 2006;73:1039-44. PMID 16570739
  33. Villegas VM, et al. Retinoblastoma. Current opinion in ophthalmology. 2013;24:581-8. PMID 24100372
  34. Antoneli CB, et al. Trilateral retinoblastoma. Pediatric blood & cancer. 2007;48:306-10. PMID 16572402
  35. Aerts I, et al. Retinoblastoma. Orphanet journal of rare diseases. 2006;1:31. PMID 16934146
  36. Cassoux N, et al. Retinoblastoma: Update on Current Management. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2017;6:290-295. PMID 28558178
  37. Abramson DH, et al. Retinoblastoma. Optometry clinics : the official publication of the Prentice Society. 1993;3:49-61. PMID 8199450
  38. Mehta M, et al. Retinoblastoma. Singapore medical journal. 2012;53:128-35; quiz 136. PMID 22337189
  39. Servodidio CA, et al. Retinoblastoma. Cancer nursing. 1991;14:117-23. PMID 2059954
  40. Jain M, et al. Retinoblastoma in Asia. Eye (London, England). 2019;33:87-96. PMID 30385881
  41. Wen X, et al. Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial. The Lancet. Child & adolescent health. 2023;7:613-620. PMID 37536351
  42. Ye H, et al. Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma: A Randomized Clinical Trial. JAMA. 2024;332:1634-1641. PMID 39432296
  43. Yousef YA, et al. The Predictive Value of the Eighth Edition of the Clinical TNM Staging System for the Likelihood of Eye Salvage for Intraocular Retinoblastoma by Systemic Chemotherapy and Focal Therapy. Journal of pediatric hematology/oncology. 2021;43:e841-e847. PMID 33769386
  44. Dunkel IJ, et al. Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022;40:3839-3847. PMID 35820112
  45. Das S, et al. Lag time for diagnosis and treatment in 1120 retinoblastoma children: Analysis from InPOG-RB-19-01. Indian journal of ophthalmology. 2025;73:1124-1131. PMID 40719713